Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
Mimma Rizzo,1 Patrizia Giannatempo,2 Camillo Porta1,3 1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; 2Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milan, Italy; 3Department of Biomedical Sciences and Human Oncology, Univers...
Guardado en:
Autores principales: | Rizzo M, Giannatempo P, Porta C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/77823714dbc345eea82281987cebfa04 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Shuo Hong, et al.
Publicado: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021) -
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Sara Elena Rebuzzi, et al.
Publicado: (2021) -
Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021) -
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Yann-Alexandre Vano, et al.
Publicado: (2021)